AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:29 2024-04-15 am EDT			5-day change	1st Jan Change
11,024 ^GBX	-0.36%		+3.90%	+4.00%

Apr. 15	AstraZeneca: expects a sharp rise in kidney disease	CF
Apr. 15	ASTRAZENECA : Barclays reiterates its Buy rating	ZD

ASTRAZENECA : Sell rating from Goldman Sachs

March 17, 2021 at 09:03 am EDT

Goldman Sachs reiterate its Sell rating. The target price is still set at GBX 6800.

Latest news about AstraZeneca PLC

AstraZeneca: expects a sharp rise in kidney disease	Apr. 15	CF
ASTRAZENECA : Barclays reiterates its Buy rating	Apr. 15	ZD
Adherium’s Hailie Smartinhaler Secures FDA Approval for Use with AstraZeneca's Airsupra and Breztri Inhalation Devices	Apr. 14	MT
Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin...	Apr. 12
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says	Apr. 12	DJ
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs	Apr. 12	MT
EU regulator finds no link between weight-loss drugs and suicidal thoughts	Apr. 12	RE
Fitch Affirms AstraZeneca Rating on Stable Position in Pharmaceutical Sector	Apr. 12	MT
Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	Apr. 11	MT
AstraZeneca Executives' Compensation Policy Passes With Low Shareholder Approval	Apr. 11	DJ
AstraZeneca shareholders approve 2024 pay policy in boost to CEO Soriot	Apr. 11	RE
AstraZeneca shareholders approve 2024 pay policy at AGM	Apr. 11	RE
European Equities Close Lower on Thursday as ECB Leaves Interest Rates Unchanged	Apr. 11	MT
FTSE 100 edges lower as financials drag	Apr. 11	RE
FTSE 100 Closes Down 0.5% Dragged by Financial Stocks After ECB Holds Rates	Apr. 11	DJ
Dwindling US Fed cut hope unnerves markets	Apr. 11	AN
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading	Apr. 11	MT
AstraZeneca Says US FDA Approves Fasenra to Treat Children Aged 6 to 11 With Severe Asthma	Apr. 11	MT
AstraZeneca: new approval for Fasenra in the USA	Apr. 11	CF
Wholesale Prices Rise Less Than Expected in March as US Equity Futures Waver Pre-Bell	Apr. 11	MT
AstraZeneca?s FASENRA Approves for Treatment of Children Aged 6 to 11 with Severe Asthma by the US Food and Drug Administration	Apr. 11	CI
Europe takes hit on nerves ahead of ECB decision	Apr. 11	AN
AstraZeneca's Board Increases 2024 Dividend by 7% to $3.10 per Share	Apr. 11	MT
Astra plans 7% dividend hike for 2024 after no rise in 2023	Apr. 11	AN
European markets mixed ahead of ECB decision	Apr. 11	AN

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , FTSE 100

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

ASTRAZENECA : AstraZeneca should not be overlooked for long

April 03, 2024 at 10:26 am EDT

'Another Good Year' Ahead for AstraZeneca: CEO Pascal Soriot

February 09, 2023 at 10:04 am EST

More Strategies

Ratings for AstraZeneca PLC

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

137.3 USD

Average target price

162.5 USD

Spread / Average Target

+18.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ASTRAZENECA PLC	+4.00%	214B
ELI LILLY AND COMPANY	+28.79%	677B
NOVO NORDISK A/S	+25.94%	560B
JOHNSON & JOHNSON	-5.84%	355B
MERCK & CO., INC.	+15.75%	319B
ABBVIE INC.	+4.32%	287B
NOVARTIS AG	+1.92%	207B
ROCHE HOLDING AG	-7.93%	199B
PFIZER, INC.	-10.00%	146B
AMGEN INC.	-7.82%	143B

Other Pharmaceuticals

AstraZeneca PLC

Equities

AZN

GB0009895292

Pharmaceuticals

ASTRAZENECA : Sell rating from Goldman Sachs

Latest news about AstraZeneca PLC

Chart AstraZeneca PLC

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for AstraZeneca PLC

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals